CD123 Mouse anti-Human, Brilliant Violet 786, Clone: 7G3, BD
Mouse Monoclonal Antibody
Manufacturer: BD Biosciences 564196
The 7G3 monoclonal antibody specifically reacts with human CD123, the 70 kDa IL-3 Receptor α (IL-3R α ) chain. CD123 associates with CD131, the 120-140 kDa Common β chain to form the IL-3 Receptor Complex. CD131 is shared with the receptors for interleukins IL-5 and GM-CSF. IL-3R α is expressed on hematopoietic progenitors and plays an important role in hematopoietic progenitor cell growth and differentiation. It is also expressed by mast cells, macrophages and a CD5+ B cell subset. This antibody has been reported to block the binding of 125I-IL-3 to high and low affinity IL-3 receptors. In functional experiments, this antibody was found to inhibit acute myeloid leukemia cell proliferation, basophil histamine release, endothelial cell-mediated IL-8 secretion, and neutrophil transmigration. This antibody has been reported to be useful for immunoprecipitation, Western blot and immunofluorescent staining for flow cytometry. At the Fifth HLDA Workshop, the human IL-3 receptor was designated CD123.
The antibody was conjugated to BD Horizon BV786 which is part of the BD Horizon Brilliant Violet family of dyes. This dye is a tandem fluorochrome of BD Horizon BV421 with an Ex Max of 405-nm and an acceptor dye with an Em Max at 786-nm. BD Horizon BV786 can be excited by the violet laser and detected in a filter used to detect Cy7-like dyes (eg, 780/60-nm filter).
|IL3RA; IL-3RA; IL-3Rα; IL-3R-alpha; Interleukin-3 receptor subunit alpha|
|Human IL-3Ra-transfected cells|
|Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.|
|Brilliant Violet 786|
|Aqueous buffered solution containing BSA and ≤0.09% sodium azide.|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok